Oruka Therapeutics, Inc.
ORKA
$9.46
-$0.165-1.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | -16.66% | -28.68% | -214.30% | ||
| Total Depreciation and Amortization | 68.18% | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -59.49% | 1,427.87% | 701.16% | ||
| Change in Net Operating Assets | 151.72% | -192.51% | 54.20% | ||
| Cash from Operations | 13.45% | -152.13% | -6,467.26% | ||
| Capital Expenditure | 79.42% | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -210,407.31% | -- | -- | ||
| Total Debt Issued | -199.46% | -- | -100.00% | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -100.00% | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -93.12% | 510.89% | -- | ||
| Cash from Financing | -90.48% | 26,767.28% | -105.69% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -186.85% | 3,235.43% | -145.50% | ||